Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels.

Davignon, Jean; Dubuc, Geneviève

Davignon, Jean; Dubuc, Geneviève.

Affiliation

Davignon J; Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal, QC H2W1R7, Canada. davignj@ircm.qc.ca

Trans Am Clin Climatol Assoc ; 120: 163-73, 2009.

Article in En | MEDLINE | ID: mdl-19768174

Subject(s)

Anticholesteremic Agents/pharmacology; Azetidines/pharmacology; Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology; Hyperlipoproteinemia Type II/drug therapy; Hyperlipoproteinemia Type II/enzymology; Serine Endopeptidases/blood; Adult; Aged; Atorvastatin; Caco-2 Cells; Case-Control Studies; Ezetimibe; Female; Genetic Variation; Hep G2 Cells; Heptanoic Acids/pharmacology; Humans; Hyperlipoproteinemia Type II/genetics; Male; Middle Aged; Mutation; Proprotein Convertase 9; Proprotein Convertases; Pyrroles/pharmacology; RNA, Messenger/genetics; RNA, Messenger/metabolism; Receptors, LDL/genetics; Serine Endopeptidases/genetics; Young Adult

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Azetidines / Serine Endopeptidases / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Hyperlipoproteinemia Type II / Anticholesteremic Agents Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2009 Type: Article

Fulltext

XML

PubMed Links

Search on Google